Daniel Wolterman Net Worth

Daniel Wolterman biography

Daniel J. Wolterman serves as Independent Director of the Company. Mr. Wolterman is currently Chief Executive Officer of Wolterman Consulting LLC, a provider of strategic and operational consulting services to healthcare providers and other entities. From January 2018 to May 2019, Mr. Wolterman served as Chief Executive Officer of ColubrisMX, Inc. and X-Cath, Inc., both privately held medical device companies. Mr. Wolterman previously served as President and Chief Executive Officer of Memorial Hermann Health System, the largest not-for-profit health system in Southeast Texas, from 2002 until his retirement from Memorial Hermann in May 2016. He has more than 38 years of experience in the healthcare industry and a long history of community involvement. Mr. Wolterman’s extensive knowledge of the healthcare industry and his executive leadership experience as President and CEO of Memorial Hermann Health System provide valuable perspective and guidance to our Board.

What is the salary of Daniel Wolterman?

As the Independent Director of Nuvasive Inc, the total compensation of Daniel Wolterman at Nuvasive Inc is $250,057. There are 8 executives at Nuvasive Inc getting paid more, with J. Christopher Barry having the highest compensation of $5,425,440.

How old is Daniel Wolterman?

Daniel Wolterman is 63, he's been the Independent Director of Nuvasive Inc since 2015. There are 2 older and 17 younger executives at Nuvasive Inc. The oldest executive at Nuvasive Inc is Donald Rosenberg, 69, who is the Independent Director.

What's Daniel Wolterman's mailing address?

Dan's mailing address filed with the SEC is 7475, Lusk Boulevard, San Diego, San Diego County, California, 92121, United States.

Insiders trading at Nuvasive Inc

Over the last 22 years, insiders at Nuvasive Inc have traded over $60,917,905 worth of Nuvasive Inc stock and bought 185,079 units worth $8,372,956 . The most active insiders traders include Jesse I Treu, James C Blair et Brian H Dovey. On average, Nuvasive Inc executives and independent directors trade stock every 11 days with the average trade being worth of $415,308. The most recent stock trade was executed by Marc W. Rosenbaum on 1 March 2023, trading 1,829 units of NUVA stock currently worth $72,703.

What does Nuvasive Inc do?

nuvasive® is a place where we create new and innovative products at a speed that drives our ability to deliver absolute responsiveness®, and gives us a competitive edge. at nuvasive, we empower our shareowners to influence results and significantly contribute to the success of the company. together we make nuvasive a leader in the spine industry with our unique focus on speed of innovation®. every member of the nuvasive family has the opportunity to improve the lives of patients through their work. these life-changing career paths show how hard work, a competitive spirit and your unwavering dedication to the patient can take you and your career to new places. in addition to being a great place to have a career, we’re also committed to giving back and supporting our communities. through an attitude of gratitude, nuvasive provides life-changing spinal surgery to disadvantaged communities through our nonprofit, the nuvasive spine foundation®, and offers patient-to-patient support through

Nuvasive Inc executives and stock owners

Nuvasive Inc executives and other stock owners filed with the SEC include:

• J. Christopher Barry,
  Chief Executive Officer, Director
• J. Christopher Barry,
  CEO & Director
• Nathaniel Sisitsky,
  Senior Vice President, General Counsel, Corporate Secretary
• Matthew K. Harbaugh,
  Exec. VP & CFO
• Gregory Lucier,
  Chairman of the Board
• Nathaniel B. Sisitsky Esq.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Lucas Vitale,
  Sr. VP & Chief HR Officer
• Donald Rosenberg,
  Independent Director
• Daniel Wolterman,
  Independent Director
• Vickie Capps,
  Independent Director
• Leslie Norwalk,
  Independent Director
• R. Scott Huennekens,
  Independent Director
• Robert Friel,
  Independent Director
• John DeFord,
  Independent Director
• Suzanne Hatcher,
  Vice President, Internal & External Affairs
• Dale Wolf,
  Senior Vice President - Global Operations
• Massimo Calafiore,
  Executive Vice President - Global Business Units
• Brent Boucher,
  Executive Vice President - Global Commercial
• Lucas Vitale,
  Chief Human Resource Officer
• Matthew Harbaugh,
  Executive Vice President, Chief Financial Officer
• Marc Rosenbaum,
  VP, Corp. Controller & Chief Accounting Officer
• Michael Farrington,
  VP of Corp. Marketing, Brand & Communication
• Juliet C. Cunningham,
  VP of Investor Relations
• Ryan Donahoe,
  Chief Technology Officer
• Dale A. Wolf,
  Sr. VP of Global Operations
• Lisa Pecora,
  VP & Head of Global Commercial Fin.
• Frank Middeke,
  Managing Director of DACH
• Sean Freeman,
  Sr. VP of Strategy & Corp. Devel.
• Johnson Lai,
  Chief Information Officer
• Jereme M Sylvain,
  Chief Accounting Officer
• Jack R Blair,
  Director
• Peter Michael Leddy,
  Director
• Edmund J Roschak,
  CEO, NuVasive Spec. Orthopedic
• Dan Wolterman,
  Director
• Michael D Ohalleran,
  Director
• Lesley H Howe,
  Director
• Peter C Farrell,
  Director
• Joan Stafslien,
  EVP and General Counsel
• Quentin S. Blackford,
  CFO and CAO
• Cox Carol,
  EVP Strategy, Corp Dev
• Tyler Lipschultz,
  EVP, Biologics
• Andrew C. Morton,
  SVP, CHRO
• Matthew Link,
  President
• Rajesh Asarpota,
  CFO
• Paul Mc Clintock,
  President, U.S. Commercial
• Stephen Rozow,
  EVP, Global Process
• Jeffrey P Rydin,
  Senior V.P., U.S. Sales
• Jason Hannon,
  VP, Legal Affairs & Secretary
• Patrick Miles,
  Senior VP, Marketing
• Kevin C Oboyle,
  CFO and Executive VP
• James C Blair,
  Director
• James J Skinner,
  VP,Strategic Sales Development
• Jonathan Spangler,
  VP & Chief Patent Counsel
• G Bryan Cornwall,
  VP, Research & Development
• Hansen A Yuan,
  Director
• Arda Minocherhomjee,
  Director
• Blair Capital Management Vi...,
  
• Perkins Caufield & Byers Vi...,
  10% owner
• Joseph Lacob,
  Director
• G Rogan Fry,
  Sr. V. P., Corp. Development
• Viii Associates Lp Kpcb,
  10% owner
• Life Sciences Zaibatsu Fund...,
  10% owner
• Iv Associates Lp Dp,
  10% owner
• Jesse I Treu,
  10% owner
• Kathleen K Schoemaker,
  10% owner
• Brian H Dovey,
  10% owner
• Vii Associates Lp Kpcb,
  10% owner
• De Depot Et Placement Du Qu...,
  10% owner
• Management Partners Iv Lpen...,
  
• Partners Iv Lp Domain,
  10% owner
• Viii Founders Fund L P Kpcb,
  10% owner
• Russell Powers,
  Exec. VP Sales Int'l Ops
• Eileen M More,
  Director
• Keith Valentine,
  President
• Alexis V Lukianov,
  CEO and Chairman
• Michael E Paolucci,
  Exec. V.P., Global HR
• Craig E Hunsaker,
  SVP, Global Human Resources
• Richard Iii Treharne,
  Director
• Michael Lambert,
  CFO and Executive VP
• Robert J Hunt,
  Director
• Siddhartha Kadia,
  Director
• Amy Belt Raimundo,
  Director
• Michael Farrington,
  SVP, People and Culture
• Marc W. Rosenbaum,
  Chief Accounting Officer